Bladder Cancer | Tumor

CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.

BCAN's First "Bladder Cancer Matters" Podcast is Now Available

February 2nd 2021

In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.

Announcing BCAN’s 2021 Young Investigator Award

January 30th 2021

The Bladder Cancer Advocacy Network (BCAN) announced that it is accepting applications for our 2021 Young Investigator Awards (YIAs).

BCAN Announces 2021 Bladder Cancer Research Innovation Award

January 26th 2021

BCAN is pleased to announce two 2021 Bladder Cancer Research Innovation Awards to support the work of investigators with exceptionally novel and creative projects with great potential to produce breakthroughs in our understanding of the management of bladder cancer.

BCAN Ranked as a Top Charity with a 4-Star Ranking for Seventh Consecutive Year

January 18th 2021

The Bladder Cancer Advocacy Network’s (BCAN’s) strong financial health and commitment to accountability and transparency have earned it a seventh consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This award puts BCAN in the top seven percent of all charities.

BCAN Applauds Bill to Provide Long-Overdue Help to Veteran Bladder Cancer Patients

January 11th 2021

The Bladder Cancer Advocacy Network (BCAN) is pleased that the U.S. Senate voted overwhelmingly to approve the National Defense Authorization Act (NDAA) which contains a critical provision that will help veterans who were exposed to Agent Orange and later developed bladder cancer.

Higher Tumor Classification and Grade for Nonmuscle-Invasive Bladder Cancer May Increase Recurrence and Progression Risk Up to Five Years

December 1st 2020

Predicting risk for recurrence and progression in patients with nonmuscle-invasive bladder cancer may help when discussing management options with clinicians.

Immunotherapy Just After Chemo May Allow Some Patients with Bladder Cancer to Maintain Health Benefits

September 30th 2020

Patients with advanced or metastatic bladder cancer, after responding to initial treatment with chemotherapy, may preserve their health improvements by starting immunotherapy immediately.

There is Help for Patients Dealing with Sexual Side Effects After Prostate, Bladder Cancer Treatment

September 30th 2020

After treatment for bladder or prostate cancer, many survivors confront permanent sexual side effects. The good news is that treatments and psychological support are available.

FDA Approves Bavencio as Frontline Maintenance Therapy in Advanced Bladder Cancer

July 1st 2020

The Food and Drug Administration approved Bavencio as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma.

Infigratinib Appears Active Across All Lines of Treatment in Patients With Advanced Bladder Cancer

June 16th 2020

"These results suggest that infigratinib has activity in patients with advanced urothelial carcinoma, regardless of the line of treatment,” says lead study author Dr. Yung Lyou.

Cabometyx-Tecentriq Combination Produces 'Encouraging Clinical Activity' in Previously Treated Bladder Cancer

June 12th 2020

At a median follow-up of 19.7 months, patients who received the combination achieved an objective response rate (the proportion of patients who had a complete or partial response to treatment) of 27%.

Bavencio Soon After Chemotherapy Improves Survival in Patients with Advanced Bladder Cancer

May 29th 2020

The immunotherapy Bavencio improves survival when given as a maintenance treatment in patients whose advanced urothelial carcinoma did not progress on platinum-based chemotherapy.

Don't Ignore the Warning Signs of Cancer, Even During a Pandemic

May 19th 2020

Even amid stay at home orders to mitigate the spread of the coronavirus, listen to your body and speak to your healthcare professionals when you are worried about a potential for cancer.

What Patients with Bladder Cancer Can Do When COVID-19 Impacts Their Care

May 16th 2020

COVID-19 has drastically changed the landscape for patients with bladder cancer, but the new challenges are not insurmountable. CURE had the chance to interview the co-founder of the Bladder Cancer Advocacy Network to discuss these changes.

How One Organization is Honoring Bladder Cancer Awareness Month During the COVID-19 Pandemic

May 14th 2020

Amid the COVID-19 pandemic, the Bladder Cancer Advocacy Network is honoring Bladder Cancer Awareness Month in a slightly different way from previous years.

Bladder Cancer

May 6th 2020

Understanding bladder cancer.

FDA's Jelmyto Approval Offers Patients 'Very Sorely Needed' Treatment Option

April 22nd 2020

The Food and Drug Administration’s approval of Jelmyto (mitomycin gel]) in low-grade upper tract urothelial cancer offers patients a much-needed treatment option, according to one expert.

Padcev and Keytruda Combination Shows Promise for More Urothelial Carcinoma Options

April 17th 2020

Data from the phase 1b/2 trial of Padcev in combination with Keytruda displayed promise for patients with metastatic urothelial carcinoma, but further research is needed.

FDA Approves First Low-Grade Upper Tract Urothelial Cancer Therapy

April 15th 2020

The Food and Drug Administration approved Jelmyto to treat patients with low-grade upper tract urothelial cancer.

Looking Toward Combination Therapies in Metastatic Bladder Cancer

April 14th 2020

Immunotherapy and targeted therapy medications have brought new hope to patients with advanced disease.

Immunotherapy After Chemotherapy Improves Outcomes in Metastatic Bladder Cancer

April 10th 2020

Using immunotherapy earlier, immediately after the conclusion of chemotherapy to treat metastatic bladder cancer, can delay the time until disease progression.

Electronic Cigarette Use and Risk of Bladder Cancer

April 2nd 2020

A new study links e-cigarette use to bladder cancer but experts say more research is needed.

Experts Call for Refined Treatment Paradigm in Urothelial Cancer

March 17th 2020

There are a number of treatment options available for patients with urothelial cancer, however, experts want to refine the current treatment paradigm amid new drugs entering the landscape.

The Future of Immunotherapy in Bladder Cancer

February 23rd 2020

Treatment for patients with bladder cancer is moving away from VEGF-targeted therapies toward immune checkpoint inhibition, according to one expert.

Padcev, Keytruda Combination Proves Impactful for Patients with Metastatic Urothelial Cancer

February 20th 2020

The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.

Padcev Combination Shows Promise in Patients with Metastatic Bladder Cancer

February 16th 2020

The combination of Padcev plus Keytruda induced a high rate of durable objective response rates in patients with locally advanced or metastatic urothelial cancer.

New Blood Test May Detect Cancer Cells in Asymptomatic Patients

February 5th 2020

A new study supported the use of a blood test to detect clusters of cancer cells in the blood of asymptomatic individuals, meaning, patients could have a non-invasive screening and testing method.

Testing Combinations in Metastatic Urothelial Cancer

January 29th 2020

Better response rates may be seen in patients with advanced bladder cancer when two therapies are combined.

2020 Bladder Cancer Research Innovation Award

January 16th 2020

The Bladder Cancer Advocacy Network announces it's Bladder Cancer Research Innovation Award.

FDA Grants Accelerated Approval to Astellas

January 14th 2020

FDA has given an accelerated approval to Padcev in the treatment of patients with locally advanced or metastatic urothelial cancer.